Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NX-2016
- Development stage
- Preclinical
- Lead developer
- Guangzhou Nanxin Pharmaceutical
- Modality
- Small Molecules
01
Overview
NX-2016 is a preclinical small molecule drug candidate being developed by Guangzhou Nanxin Pharmaceutical for the treatment of influenza. It is characterized by a novel, non-neuraminidase mechanism of action, distinguishing it from standard-of-care neuraminidase inhibitors like oseltamivir and peramivir. The drug is intended to provide broad-spectrum activity against various influenza strains, including drug-resistant variants, avian influenza, and H1N1 pandemic strains. Currently, NX-2016 is in the candidate identification stage of development, representing an early-stage effort to address unmet needs in influenza therapy through a unique antiviral approach.
- Other names
- 候选化合物 NX-2016
Beyond the preview
Go deeper on NX-2016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NX-2016.